Sister Ecosystem:Paired with the LEVL Protocols App for 1-click execution & adherence tracking
Epistemic Rigor & Clinical Standards

Scientific Methodology & Mathematical Logic

LongevityReviews.org operates as an open, evidence-anchored consensus platform for human longevity science. Rather than relying on editorial opinions or influencer anecdotes, every score across our platform is computed using peer-reviewed clinical research, established epidemiological frameworks, and reproducible mathematical algorithms.

Governing Standards:Oxford CEBMGRADE FrameworkCochrane RoB 2López-Otín (2023)
Foundational Frameworks

Adherence to Global Clinical Standards

Wherever accepted international methodologies exist for rating clinical evidence, we adhere to them strictly rather than inventing proprietary black boxes.

Oxford CEBMStudy Hierarchy
Centre for Evidence-Based Medicine

Hierarchical study design weighting: Systematic Reviews & Meta-Analyses (Level 1) down to In Vitro assays (Level 5).

GRADE FrameworkEvidence Quality
Grading of Recommendations Assessment

International consensus standard for evidence certainty: High (A), Moderate (B), Low (C), and Very Low (D).

Cochrane RoB 2Bias Auditing
Risk of Bias 2 Tool

Systematic auditing of randomization, blinding, selective reporting, and commercial conflict-of-interest penalties.

López-Otín (2023)Cellular Biology
The 12 Hallmarks of Aging

Cellular damage mapping across Primary, Antagonistic, and Integrative hallmarks with exponential saturation modeling.

8 Canonical VectorsPhysiology
Organ-Specific Clinical Biomarkers

Actionable physiological mapping anchored to hard clinical endpoints (ApoB, VO2 Max, HOMA-IR, hs-CRP, DEXA BMD).

0–99 CEI IndexScoring Model
Clinical Efficacy Index

Multi-parametric 4-factor deterministic scoring model: evidence grade, effect magnitude, specificity, and reproducibility.

Section 1: The 0–99 Scale

The Deterministic 0–99 Clinical Efficacy Index (CEI)

All functional outcomes and longevity metrics are calibrated on a continuous 0–99 integer scale. We deliberately avoid a 100-point ceiling because in biological sciences, declaring 100% certainty is scientifically invalid. Furthermore, a 0–99 scale provides the necessary statistical resolution to separate high-performing protocols from elite physiological anchors without compression.

The Governing Equation
Score = Clamp₀⁹⁹( S_evidence + S_magnitude + S_endpoint + S_reproducibility - Δ_bias )

Where each dimension is evaluated against a verified empirical ledger of published clinical trials.

1Evidence Quality (S_evidence)35% Weight · Max 35 pts

Anchored to the Oxford CEBM study hierarchy:

  • • Cochrane Review / Meta-Analysis:34–35 pts
  • • Double-Blind Placebo RCT:30–33 pts
  • • Prospective Human Cohort (N > 500):25–29 pts
  • • ITP Lifespan / Animal Biomarker:20–24 pts
  • • Observational / In Vitro:12–19 pts
2Effect Size (S_magnitude)35% Weight · Max 35 pts

Derived directly from quantitative biomarker deltas or Cohen's d:

  • • Very High (d ≥ 0.80 or ≥ 25% delta):32–35 pts
  • • High (d = 0.50–0.79 or 12–24% delta):27–31 pts
  • • Moderate (d = 0.30–0.49 or 5–11% delta):20–26 pts
  • • Mild / Secondary Cross-Talk (< 5%):12–19 pts
3Endpoint Specificity (S_endpoint)20% Weight · Max 20 pts

Assesses whether the intervention acts directly on the target tissue or through indirect downstream cascades:

  • • Direct Primary Tissue Target:19–20 pts
  • • Secondary Downstream Signaling:14–18 pts
  • • Correlative / Tertiary Cross-Talk:8–13 pts
4Onset & Reproducibility (S_repro)10% Weight · Max 10 pts

Reflects latency to clinical manifestation and human responder consistency:

  • • Acute / Deterministic (< 60 min, 100%):9–10 pts
  • • Sub-acute (1–4 weeks, high responder):7–8 pts
  • • Chronic (8–24 weeks, variable response):4–6 pts
Section 2: Multi-Study Synthesis

Multi-Study Epistemic Weighting & Bias Auditing

When multiple published trials exist for an intervention, we do not simply take the best result or an unweighted average. Instead, each trial is weighted according to sample size log-scaling, trial design hierarchy, and Cochrane Risk of Bias scores.

log₁₀

Sample Size Log-Scaling

Sample power is scaled logarithmically:f(N) = min(1.4, max(0.5, log₁₀(N + 10) / 3.0))This ensures an N=1,500 multi-center trial properly anchors the score over an N=14 pilot study without skewing calculations to infinity.

RoB

Cochrane Risk of Bias 2

Trials receive a risk-of-bias score from 1.0 (minimal risk) to 5.0 (high risk):Penalty = 1.0 - ((RoB - 1.0) / 4.0) × 0.22Trials with unblinded participants, missing attrition logs, or heavy industry funding are penalized up to 22%.

±%

Dynamic Confidence Intervals

Every score presents an explicit error boundary based on literature depth:CI = ± max(1.6, min(6.5, 14.0 / √(k × log₁₀(N+10))))Well-researched anchors (Creatine, Zone 2) narrow to ±1.8%, while emerging molecules widen to ±4.2%.

Section 3: Biological Grounding

Dual-Radar Mapping: 12 Hallmarks & 8 Canonical Vectors

To bridge microscopic cellular mechanisms with macro physiological health, every modality in LongevityReviews is evaluated across two distinct clinical coordinate systems:

Cellular Framework

The 12 Hallmarks of Aging

Derived from López-Otín et al. (Cell 2013, 2023), categorized into three evolutionary tiers:

Primary Hallmarks (Root Causes of Damage):Genomic Instability, Telomere Attrition, Epigenetic Alterations, Loss of Proteostasis, Disabled Macroautophagy.
Antagonistic Hallmarks (Compensatory Responses):Deregulated Nutrient Sensing, Mitochondrial Dysfunction, Cellular Senescence.
Integrative Hallmarks (Systemic Culprits):Stem Cell Exhaustion, Altered Intercellular Communication, Chronic Inflammation, Dysbiosis.
Clinical Physiology

The 8 Canonical Longevity Vectors

Actionable organ and system domains anchored directly to measurable laboratory biomarkers:

Heart Health
ApoB, CAC, BP
Brain Longevity
fMRI, BDNF, SWS
Metabolic Health
HOMA-IR, Fasting Insulin
Cancer Defense
Autophagy, Senescence
Testosterone
Free T, SHBG, DHEA
Chronic Inflammation
hs-CRP, IL-6, TNF-α
Bone Density
DEXA T-Score, Trabecular
Cellular Longevity
DunedinPACE, GrimAge
Section 4: Stacking & Multi-Pillar Potential Fulfillment

Differentiated Physiological Potential Mathematics

In human biology, achieving 90% of your physiological potential for Muscular Strength is fundamentally different than achieving 90% for Sleep Onset Latency. A universal flat formula distorts reality. Our epistemic framework introduces a crucial two-tier distinction:

Tier 1: Modality Clinical Efficacy (0–99)

Measures the isolated, peer-reviewed human RCT evidence of a single intervention. On modality pages, Resistance Training is rated 98/100 for Muscular Strength because it is the undisputed gold-standard mechanical stimulus in clinical literature.

Tier 2: Protocol Potential Fulfillment (0–97)

Measures what percentage of total human potential is fulfilled by a complete protocol. Doing only heavy lifting without protein substrate, cellular creatine, and deep sleep leaves ~33% of strength potential on the table, fulfilling only 67% of total potential.

The Four Mechanistic Physiological Complexity Classes

Class A: Acute Triggers
Single Anchor Cap: ~78–80%

Signal-gated biophysical switches (Sleep Latency, Alertness, Satiety, Calmness). A single landmark modality unlocks ~80% of human potential.

Class B: Dual-Pillar Recovery
Single Anchor Cap: ~74–76%

Homeostatic balancing (Soreness/DOMS, Stress, Mood, Digestive Comfort). Requires co-equal thermal/vagal flush combined with cellular hydration.

Class C: Coupled Systems
Single Anchor Cap: ~70–73%

Central vs. peripheral limits (Endurance, Energy, Focus, Sleep Architecture). Requires pairing central cardiac/PFC limits with peripheral cellular engines.

Class D: Multi-System Structural
Single Anchor Cap: ~66–68%

Tissue synthesis (Strength, Joint Comfort, Skin, Immune, Bone). Strictly requires Stimulus + Substrate + Cellular Bioenergetics + Slow-Wave Rest.

Multi-Pillar Potential Fulfillment Equations
S_1 = E_1 × α_outcome
S_i = S_{i-1} + (100 − S_{i-1}) × (E_i / 100) × w_{o, i}
S_final = min(97, round(S_k))

Where $E_1 \ge E_2 \ge \dots$ are constituent modality clinical ratings, $\alpha_o$ is the outcome-specific biological ceiling factor, and $w_o$ is the orthogonal expansion vector. 100/100 is eliminated as a biologically unattainable asymptote.

Worked Biohacker Stacking Scenarios
Muscular Strength (Class D Multi-System):
  • • Lifting Alone (98) → 67/100 (Leaves 33% unfulfilled)
  • • + Protein Distribution (94) → 80/100 (Unlocks amino substrate)
  • • + Creatine Monohydrate (91) → 86/100 (Intramuscular phosphocreatine)
  • • + Deep Sleep Recovery (85) → 88/100 (Anabolic GH pulse)
Sleep Onset Latency (Class A Acute Trigger):
  • • 65°F Cool Dark Room (95) → 76/100 (Core temperature dump)
  • • + Glycine / Apigenin (90) → 86/100 (Central GABAergic disinhibition)
  • • + Morning Sunlight (88) → 89/100 (SCN circadian phase-advance)
  • • Elite Multi-System Sleep Blueprint → 91/100

The 8 Systemic Longevity Vectors: Organ-System Potential Fulfillment

Single-Modality Ceiling: ~65–68%

While daily wellbeing outcomes track immediate functional performance, the 8 Systemic Longevity Vectors represent the chronic structural resilience of major organ systems. Because organ failure or degenerative decline emerges through multiple orthogonal pathways, no single intervention can ever provide complete protection. For example, practicing Zone 2 Cardio with elite consistency produces a pristine clinical trial efficacy rating (98/100), yet fulfills only 66% of total cardiovascular longevity potential if circulating ApoB particles, left ventricular stroke volume (Zone 5 / VO2 Max), and arterial calcification remain unaddressed.

1. Cardiovascular Longevity (heart_health)Ceiling: 66%
  • Pillar 1: Endothelial Protection & Nitric Oxide (Zone 2)
  • Pillar 2: ApoB Clearance & Plaque Stasis (Lipid control)
  • Pillar 3: Peak VO2 Max Stroke Volume (Zone 5 HIIT)
  • Pillar 4: Arterial Decalcification & Elasticity (K2/MK-7, BP)
2. Neurocognitive Longevity (brain_longevity)Ceiling: 66%
  • Pillar 1: Glymphatic Clearance (Slow-wave deep sleep)
  • Pillar 2: Hippocampal Neuroplasticity & BDNF (Cardio / Sauna)
  • Pillar 3: Cerebral Perfusion & Nitric Oxide (Vascular flow)
  • Pillar 4: Neuroinflammation Dampening (Omega-3 DHA/EPA)
3. Metabolic Flexibility (metabolic_health)Ceiling: 67%
  • Pillar 1: GLUT4 Translocation & Muscle Glucose Sink (Resistance)
  • Pillar 2: Hepatic Fatty Acid Oxidation & Ketogenesis (Fasting)
  • Pillar 3: Mitochondrial Substrate Switching (Zone 2)
  • Pillar 4: Postprandial Glycemic Attenuation (Fiber, Berberine)
4. Cancer Interception (cancer_defense)Ceiling: 65%
  • Pillar 1: Natural Killer (NK) Cell Immunosurveillance (Exercise)
  • Pillar 2: Mutagenic Stress Reduction & DNA Repair (Sulforaphane)
  • Pillar 3: Growth Factor Normalization (IGF-1 / mTOR cycling)
  • Pillar 4: Multi-Cancer Early Detection (Liquid Biopsy / MRI)

The 12 Hallmarks of Aging (López-Otín et al., 2023): Cellular Damage Saturation Engine

Single-Modality Ceiling: ~64–68%

The 12 Hallmarks of Aging represent the root molecular and cellular drivers of organismal decline. The engine classifies hallmarks into their canonical three-tier hierarchy: Primary (initiating molecular damage), Antagonistic (adaptive responses that turn deleterious at chronicity), and Integrative (macroscopic tissue failure).

Worked Hallmark Stacking Scenario: Cellular Senescence (Integrative / Antagonistic)

Cellular senescence involves irreversible cell cycle arrest coupled with a hyper-inflammatory Senescence-Associated Secretory Phenotype (SASP). A pure senolytic modality (e.g., high-dose Fisetin) achieves an exceptional clinical trial efficacy score (93/100), but only fulfills 65% of the potential on this hallmark because killing senescent cells without suppressing the SASP in surviving cells, stimulating autophagic clearance, or supporting NK-cell mediated elimination leaves underlying paracrine toxicity unaddressed.

Pillar 1: SenolysisFisetin / Dasatinib
Pillar 2: SASP SuppressionApigenin / Metformin
Pillar 3: Immune ClearanceZone 2 Aerobic Flow
Pillar 4: Replicative ShieldingMitochondrial CoQ10
• Fisetin Alone (93) → 65/100  |  + SASP Inhibitor (88) → 79/100  |  + Exercise Clearance (85) → 86/100  |  Full 4-Pillar Synergy → 92/100
Section 5: Data Schema & Systems Architecture

The Tripartite Taxonomy & 2-Tier Data Architecture

LongevityReviews.org acts as the public consensus intelligence layer, while the LEVL Protocols App acts as the personal adherence, daily routine tracking, and wearable verification layer. Both applications query and update the same unified Supabase schema.

LEVL Ecosystem Taxonomy

The 25 Practical Daily Wellbeing Outcomes

Synchronized with LEVL Mobile App

These 25 canonical tracking slugs represent the exact daily wellness objectives users select and monitor in the LEVL app:

Mood(mood)Energy(energy)❤️Stress(stress)Alertness(alertness)🧠Focus(focus)🛡️Soreness(soreness)🛡️Pain(pain)🏋️Strength(strength)🥗Satiety(satiety)🌱Digestive Comfort(digestive_comfort)🧠Brain Fog(brain_fog)🌙Sleep Quality(sleep_quality)🌅Waking Restedness(waking_restedness)🌙Sleep Latency(sleep_latency)🏃Endurance(endurance)🧠Memory(memory)❤️Calmness(calmness)❤️Emotional Resilience(emotional_resilience)🦴Joint Comfort(joint_comfort)Motivation(motivation)📈Productivity(productivity)🛡️Immune Resilience(immune_resilience)Skin Clarity(skin_clarity)❤️‍🔥Libido(libido)🧠Mental Clarity(mental_clarity)
+ The 8 Biological Longevity Vectors:heart_health, brain_longevity, metabolic_health, cancer_defense, testosterone, chronic_inflammation, bone_density, cellular_longevity.
+ The 12 Hallmarks of Aging:genomic_instability, telomere_attrition, epigenetic_alterations, loss_of_proteostasis, macroautophagy, nutrient_sensing, mitochondria, senescence, stem_cells, intercellular_comm, inflammation, dysbiosis.

Where We Draw the Separation Line: Comparability vs. Distinctiveness

A fundamental dilemma in health platform design is balancing cross-modality comparability (e.g. sorting and filtering protocols) with scientific distinctiveness (capturing the precise biological mechanism of a specific compound). We solve this using a strict 2-Tier Architecture:

Tier 1: Canonical Bucket (Strict Enum)Comparability

The Grouping & Query Key

The database key (in functional_outcomes_to_track and functional_impacts) MUST always be one of the standardized canonical slugs. This guarantees:

  • Instant filtering and cross-modality leaderboard sorting
  • Reliable multi-protocol radar chart stacking
  • 100% interoperability with user goal pickers in the LEVL mobile app
Tier 2: Clinical Payload (Metadata)Distinctiveness

The Granular Scientific Proof

Inside each canonical bucket, the modality attaches its specific clinical findings, keeping scientific nuances fully preserved without polluting the grouping keys:

  • Specific biomarker measured (e.g. ³¹P-MRS prefrontal phosphocreatine)
  • Quantitative delta and p-value (+9.2% ATP resynthesis, p=0.003)
  • Exact peer-reviewed PubMed citations (PMID 33578876)
Database FieldData TypeDescription & Operational RoleExample Value
primary_outcometextHeadline clinical objective of the intervention"Muscular Strength & Cognitive Bioenergetics"
secondary_outcomestext[]Array of 3–5 secondary clinical endpoints["Working Memory", "Bone Mineral Density"]
functional_outcomes_to_tracktext[]Standardized LEVL snake_case tracking slugs (from the 25 canonical options)["strength", "focus", "energy", "recovery"]
functional_impactsjsonbTitle Case mapping of 0–99 score, magnitude & distinctive studies{"Strength": {"score": 96, "effect_magnitude": "very_high"}}
modality_studiesrelational tableGranular trial ledger with PMIDs, sample size & delta %PMID 14636102 (N=500+, 1RM strength +14%)
Section 6: Editorial Charter

Strict Editorial Independence & Commercial Disclosures

Zero Paid Rankings:No supplement brand, clinic, or hardware manufacturer can pay to boost a modality, vector, or outcome score.
Separation of Entity:Commercial product formulations and clinic offerings are segregated from pure scientific modality consensus evaluations.
Open Debate & Steel-Manning:Contested compounds (such as Metformin in non-diabetics or NMN bioavailability) maintain balanced debate arenas with peer-reviewed citations from both camps.

Explore the Evidence Consensus